 Home > Medical News > Latest Medical News > Frequent changes in senior management of pharmaceutical companies: Chairman and general manager of many pharmaceutical companies leave

Frequent changes in senior management of pharmaceutical companies: Chairman and general manager of many pharmaceutical companies leave

 Last Update: 2021-09-05
 Source: Internet
 Author: User

Tags

lyondell chemical company

editorial board

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The high-level changes of pharmaceutical companies are still frequent.
In just over a month, the chairman of six pharmaceutical companies resigned
.

Change of chairman of 6 well-known pharmaceutical companies

Recently, executives in the pharmaceutical industry have continued to change frequently
.

According to Cyberlane's incomplete analysis, from July to now, the chairman of six pharmaceutical companies has changed

Jiaying Pharmaceutical

On August 2, Guangdong Jiaying Pharmaceutical Co.
, Ltd.
issued the "Announcement on the Election of the Chairman and the Appointment of the General Manager" and the "Announcement on the Election of the Vice Chairman"
.

The announcement stated that the company held the first meeting of the sixth board of directors on August 2, 2021, and reviewed and approved the "Proposal on Election of Mr.

Yunnan Lvsheng Chinese Medicine Technology Co.
, Ltd.

On July 28, Yunnan Lvsheng Chinese Medicine Technology Co.
, Ltd.
issued an announcement stating that the company’s board of directors received a resignation report from Chairman Xiong Shurong on July 26, and the resignation will take effect on July 26, 2021
.

Zhongxin Pharmaceutical

On July 20, Zhongxin Pharmaceutical issued an announcement stating that the board of directors received Li Liqun’s written resignation application on July 19, 2021
.

The announcement showed that Li Liqun applied for resignation as director and chairman of the company due to job changes

Beike Bio

On July 13, Beike Biotech issued an announcement stating that the company’s board of directors had recently received an application for resignation from director An Jixiang
.

As he reached the legal retirement age, Mr.

Hengrui Medicine

On July 9, Hengrui Medicine issued an announcement stating that the company’s board of directors had recently received a resignation report from the company’s chairman and general manager Zhou Yunshu.
Zhou Yunshu applied for resignation from the company’s chairman, general manager and the corresponding positions of the special committee of the board of directors due to physical reasons.
The resignation report is from Effective from the date of delivery to the company’s board of directors
.

It is reported that on August 4, Hengrui official announced that Sun Piaoyang became chairman of the board

Yan'an Bikang

On July 7, Yan'an Bikang issued the "Announcement on the Resignation and By-election of Certain Directors and Senior Executives".
The content of the announcement shows that Yan'an Bikang has recently received 6 The resignation report of two senior executives, and the board of directors was held on July 5 to review the appointment of new management
.

According to the company's announcement, Yanan Bikang's senior executives who resigned this time include Chairman Gu Xiaojia, Vice Chairman Li Jingkun, Directors He Yudong, Deng Qing, Wang Dong, and Vice President Yue Hongbo
.

In addition, the company held a board of directors and agreed to nominate Han Wenxiong, Shao Xinjun, Wang Cheng, Quan Xinxue, and Cui Qingwei as non-independent director candidates for the company's fifth board of directors.

Changes in the management of more than 10 pharmaceutical companies

In addition to the changes in the chairman of the six pharmaceutical companies mentioned above, according to Cybernet, from July 2021 to the present, there are also:

Huaren Pharmaceutical Co.
, Ltd.
Shu Wen applied to resign from the position of vice president; Boji Pharmaceutical Biotechnology Co.
, Ltd.
Wang Jianhua applied to resign from the position of director and deputy general manager; Luoxin Pharmaceutical Co.
, Ltd.
Chen Da applied to resign from the company’s financial manager and other positions; Hainan Taosheng Pharmaceutical Co.
, Ltd.
Chen Qiubo applied to resign as secretary to the company's board of directors; Wanan Pharmaceutical Han Tianyu applied to resign as deputy general manager of the company; Renhe Pharmaceutical Yang Feng applied to resign as an independent director of the company; Dongya Pharmaceutical Xu Zhijian applied to resign as secretary to the board of directors; Ji'an Yisheng Pharmaceutical industry Ding Fujun applied to resign as deputy general manager; Fukang Pharmaceutical Yuan Min applied to resign as deputy general manager; Lifang Pharmaceutical Gao Meihua applied to resign as director and deputy general manager; Harbin Sanlian Guan Chengshan applied to resign from the company’s deputy general manager
.

According to incomplete statistics from Cyber Blue, in just over a month, nearly 11 pharmaceutical companies have experienced high-level personnel changes
.

In general, the main reasons for these corporate executives to leave are job changes and personal reasons

Industry adjustment drives talent flow

In fact, the flow of management personnel in pharmaceutical companies has been relatively frequent
.

In addition to the continuous adjustment of the personnel structure of local pharmaceutical companies, multinational pharmaceutical companies are also constantly planning

For example: In August, according to the "Medicine Representative" public account, Peng Zhenke, the founder and partner of the medical consulting company INNOVie, joined Pfizer as the president of Pfizer Biopharmaceutical Group China; in June, the former general manager of Roche's first business unit and general medicine Qian Wei, the acting head of Specialty Medicines Division, joined Junshi Bio; in May, Wang Yizhe, the former head of global R&D of Eli Lilly's anti-tumor products, joined Liantuo; in February, Ji Jing, former vice president of AstraZeneca China R&D, joined Heyu Pharmaceutical
.

Larger display space and higher salaries have made local pharmaceutical companies more attractive to many high-level managers of multinational pharmaceutical companies.
Kind of trend
.

With the normalization of centralized procurement, the adjustment of the medical insurance catalogue and the gradual implementation of the national talks, the profit margins of some pharmaceutical companies have been continuously squeezed.
To a certain extent, the development strategies of pharmaceutical companies have been affected, forcing pharmaceutical companies to Choosing to reduce costs, reduce expenditures, and adjust the strategic structure, in this context, frequent changes in pharmaceutical company executives are also expected
.

According to the analysis of the "2021 Market Outlook and Salary Report" released by Randstad Greater China, one of the world's largest human resource service solution providers, salary and benefits, work pressure, and career development opportunities have become the main reasons for the medical and health practitioners to switch jobs
.

It is foreseeable that under the continuous transformation and upgrading of the pharmaceutical industry, there are higher requirements for the standards of talents.
Pharmaceutical workers should follow the company's strategic adjustments and actively seek their own career choices
.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.